Thank you, Mr. Chair.
Thank you for being here today.
If we can go back to the first-line and second-line medication, we're actually increasing costs, and one of the keys here is to keep the expenses down. Can you explain to me, and I'm not quite clear on this, how the one licence system will actually help in a developing country?
If it's too expensive at one level, even if it's cheaper than what you're paying in developed countries, how do we get it to the people who need it? You mentioned I think it was $150 versus $1,000, if I'm not mistaken. All of a sudden $1,000, you mentioned bringing it down to $650. It's still more than they can afford.
What worries me, and I'm trying to figure out where the benefit is, is if we come up with something that says okay, we'll allow the drugs to go in, they're still too expensive. There's no use on the ground. How do we get around that? I'm not quite clear on the benefit at the tail end if it's still too expensive.